Related Experiment Video
Updated: May 16, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Targeting PCSK9, APOB, and CETP at the Transcriptome Level by hsa-miR-30b-3p Reduces LDL-Associated Protein in Huh-7
Hani Keshavarz Alikhani1, Zahra Hendi1, Mahsa Salehi2
1Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Molecular Biology Reports
|May 14, 2026
Summary
MicroRNA miR-30b-3p targets key genes involved in cholesterol metabolism, reducing low-density lipoprotein (LDL) levels. This suggests miR-30b-3p is a potential therapeutic for hypercholesterolemia.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Hypercholesterolemia, marked by high LDL-C, is a significant cardiovascular disease risk factor.
- MicroRNAs (miRNAs) are crucial regulators of gene expression and lipid metabolism.
Purpose of the Study:
- Investigate miR-30b-3p's role in lipid metabolism.
- Determine miR-30b-3p's effect on target genes and hypercholesterolemia.
Main Methods:
- In silico analysis to predict miR-30b-3p targets.
- Dual luciferase reporter assays to validate binding sites.
- Overexpression of miR-30b-3p in Huh-7 cells via lentiviral transduction.
- Quantitative PCR and Western blot to assess gene and protein expression.
- Measurement of LDL and HDL-associated proteins in cell culture supernatant.
Main Results:
- miR-30b-3p validated to target PCSK9, APOB, and CETP.
- Overexpression reduced PCSK9 and APOB mRNA and protein levels.
- Significant reduction in reporter activity for PCSK9 (49%), APOB (39%), and CETP (86%).
- Hepatocyte miR-30b-3p overexpression decreased LDL-associated proteins, lowering the LDL/HDL ratio.
- miR-30b-3p demonstrated a regulatory role in lipid metabolism by targeting PCSK9 and APOB.
Conclusions:
- miR-30b-3p effectively targets PCSK9 and APOB, impacting lipid metabolism.
- miR-30b-3p shows potential as a therapeutic agent for hypercholesterolemia.
- Further in vivo studies are warranted to validate these findings.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...